| Description | This product is a monoclonal antibody derived from Human (Homo sapiens), which can specifically recognize Influenzavirus A Subtype H3N2 Hemagglutinin. The antibody is expressed with mammalian cell transient expression system, serum-free and purified by affinity chromatography. The purity and integrity are tested via SDS-PAGE and SEC-HPLC analysis. Given an antigen, additional QC measures are also desired such as affinity testing and binding validation. Specifically, the antibody is provided in multiple formats for in vivo and in vitro assays. The Invivo version features greater than 95% purity, ultra-low endotoxin levels (<1 EU/mg or 0.1 EU/mg), and is preservative, stabilizer, and carrier protein-free. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Influenzavirus A Subtype H3N2 |
| Isotype | IgG |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and/or SEC-HPLC |
| Endotoxin | <1 EU/mg, determined by LAL method |
| Purification | Protein A affinity purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4⁰C within a week. For longer storage, aliquot and store at -20⁰C. |
| Application | ELISA; WB; DB; Neut |
| Application Notes | The antibody is recommended for detection of H3N2 HA by Neut assay. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | H3N2 HA |
| Alternative Name | Hemagglutinin; HA; H3N2; Influenza A virus |
| UniProt | Q91MA7 |
| Research Area | Microbiology; Infectious Disease |
Figure 1 Recombinant Human Anti-H3N2 HA Monoclonal Antibody (V3S-0522-YC7218) in SDS-PAGE
SDS-PAGE analysis of V3S-0522-YC7218 in non-reduced (Lane 1, 1.5 μg) and β-mercaptoethanol-reduced (Lane 2, 1.5 μg) and non-reduced (Lane 2, 1.5 μg) conditions. Gel stained for 30 minutes with Coomassie Blue. As a result, different β-mercaptoethanol-reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively.
Figure 1 Recombinant Human Anti-H3N2 HA Monoclonal Antibody (V3S-0522-YC7218) in SDS-PAGE
Figure 2 Recombinant Human Anti-H3N2 HA Monoclonal Antibody (V3S-0522-YC7218) in SEC-HPLC
The purity of V3S-0522-YC7218 was greater than 95% as determined by SEC-HPLC.
Column: 3 µm, 7.8 x 300 nm
Mobile phase: 150 mM Sodium Phosphate Buffer, pH 7.0
Detection: UV 280 nm
Injection: 10 µl
Figure 2 Recombinant Human Anti-H3N2 HA Monoclonal Antibody (V3S-0522-YC7218) in SEC-HPLC
Figure 3 Recombinant Human Anti-H3N2 HA Monoclonal Antibody (V3S-0522-YC7218) in ELISA
ELISA analysis of V3S-0522-YC7218 was performed by coating with Influenza A H3N2 (A/Perth/16/2009) Hemagglutinin / HA Protein (His Tag). Then blocked with BSA and incubated with V3S-0522-YC7218. The HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
Figure 3 Recombinant Human Anti-H3N2 HA Monoclonal Antibody (V3S-0522-YC7218) in ELISA
Figure 4 Recombinant Human Anti-H3N2 HA Monoclonal Antibody (V3S-0522-YC7218) in ELISA
ELISA analysis of V3S-0522-YC7218 was performed by coating with Influenza A H3N2 (A/Victoria/210/2009) Hemagglutinin / HA Protein (His Tag). Then blocked with BSA and incubated with V3S-0522-YC7218. The HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
Figure 4 Recombinant Human Anti-H3N2 HA Monoclonal Antibody (V3S-0522-YC7218) in ELISA
Figure 5 Recombinant Human Anti-H3N2 HA Monoclonal Antibody (V3S-0522-YC7218) in WB
Western blot analysis of V3S-0522-YC7218 was performed by loading Influenza A H3N2 (A/Perth/16/2009) Hemagglutinin / HA Protein (His Tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with V3S-0522-YC7218 and HRP goat anti-Human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.
Lane 1: Reduced antigen (0.3 μg)
Lane 2: Reduced antigen (0.6 μg)
Figure 5 Recombinant Human Anti-H3N2 HA Monoclonal Antibody (V3S-0522-YC7218) in WB
Figure 6 Recombinant Human Anti-H3N2 HA Monoclonal Antibody (V3S-0522-YC7218) in WB
Western blot analysis of V3S-0522-YC7218 was performed by loading Influenza A H3N2 (A/Victoria/210/2009) Hemagglutinin / HA Protein (His Tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with V3S-0522-YC7218 and HRP goat anti-Human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.
Lane 1: Reduced antigen (0.3 μg)
Lane 2: Reduced antigen (0.6 μg)
Figure 6 Recombinant Human Anti-H3N2 HA Monoclonal Antibody (V3S-0522-YC7218) in WB
Figure 7 Recombinant Human Anti-H3N2 HA Monoclonal Antibody (V3S-0522-YC7218) in DB
Dot Blot analysis of V3S-0522-YC7218 was performed by coating with Influenza A H3N2 (A/Perth/16/2009) Hemagglutinin / HA Protein (His Tag).
V3S-0522-YC7218 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000)
Figure 7 Recombinant Human Anti-H3N2 HA Monoclonal Antibody (V3S-0522-YC7218) in DB
Figure 8 Recombinant Human Anti-H3N2 HA Monoclonal Antibody (V3S-0522-YC7218) in DB
Dot Blot analysis of V3S-0522-YC7218 was performed by coating with Influenza A H3N2 (A/Victoria/210/2009) Hemagglutinin / HA Protein (His Tag).
V3S-0522-YC7218 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-Human IgG as a secondary antibody (1: 2000)
Figure 8 Recombinant Human Anti-H3N2 HA Monoclonal Antibody (V3S-0522-YC7218) in DB
